Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02790944 · ClinicalTrials.gov registry record
Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer
A clinical trial of Pancreatic Ductal Adenocarcinoma, sponsored by Ambry Genetics.
- Completed
- Registry status
- 300
- Enrollment target
- 3
- Study locations
NCT02790944: Completed study of Pancreatic Ductal Adenocarcinoma, sponsored by Ambry Genetics.
NCT02790944 is a study of Pancreatic Ductal Adenocarcinoma that has completed, run by Ambry Genetics. The registered enrollment target is 300 participants, below the 597-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (50% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02790944, a study of Pancreatic Ductal Adenocarcinoma, has completed, sponsored by Ambry Genetics.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary objective of the study will be to estimate the prevalence of germline mutations in patients who present consecutively within 12 weeks of a confirmed diagnosis of pancreatic ductal adenocarcinoma.
Primary Outcome
The primary objective of the study will be to estimate the prevalence of germline mutations in patients who present consecutively to the clinical site within 12 weeks of a histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma.
Conditions Studied
Interventions
- GENETIC Multi-gene Next Generation Sequencing Panel
Study Locations (3)
Arizona
- HonorHealth Research Institute - Scottsdale
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2016-05-04 |
| Est. Completion | 2020-08-15 |
What the finished NCT02790944 record still lists
NCT02790944 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 597-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Multi-gene Next Generation Sequencing Panel is the first listed.
NCT02790944 reports a single indexed study location in Arizona, Massachusetts, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02790944 about?
NCT02790944 is a clinical study titled "Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer". The primary objective of the study will be to estimate the prevalence of germline mutations in patients who present consecutively within 12 weeks of a confirmed diagnosis of pancreatic ductal adenocarcinoma.
What is the current status of trial NCT02790944?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2016-05-04. Estimated completion is 2020-08-15.
What conditions does trial NCT02790944 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT02790944?
The interventions under investigation include: Multi-gene Next Generation Sequencing Panel (GENETIC).
Who is sponsoring clinical trial NCT02790944?
This trial is sponsored by Ambry Genetics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02790944 being conducted?
This trial has 3 study locations across Arizona, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02790944's enrollment target sits among peer trials
300 21st of 84 higher than 64 of 84 other Pancreatic Ductal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Ductal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
RECRUITING
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI